New Treatment Options in Multiple Myeloma

The optimal management of smoldering multiple myeloma (SMM) remains a controversial topic in treatment of myeloma. To optimize patient outcomes, oncology nurses need to understand the risks and benefits of early intervention for SMM based on risk stratification and the importance of enrolling patients in clinical trials, examining early intervention and evaluating options for best therapy.  

For patients with active MM, the key to maximizing outcomes for patients lies in careful choice of treatment regimens along with early recognition and management of treatment and disease-related side effects. Oncology nurses should understand the evolving therapeutic options available and the side effects related to those treatments as well as the current guidelines in the context of the patient's previous therapy and disease history to navigate the various options available. 

MRD is an evolving marker for disease remission and treatment outcome in MM; this is still being developed and implemented to find the optimal place in therapy. Oncology nurses should be aware of the uses and potential benefits of MRD in MM therapy and the treatment course of MM patients.

Target Audience

This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Describe indications for treatment of smoldering myeloma.
  • Provide examples of new treatment options, toxicity profiles, and management in multiple myeloma.
  • Discuss the role of minimum residual disease (MRD) in the monitoring of multiple myeloma.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.

This educational activity is supported by an educational grant from GlaxoSmithKline.

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
11/01/2021
Course expires: 
11/01/2022
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

Yi Lisa Hwa, APRN, CNP, DNP
Mayo Clinic Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, 
re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Yi Lisa Hwa, APRN, CNP, DNP
Akcea Therapeutics, Inc.: Honoraria 
sanofi-aventis U.S.: Honoraria

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Available Credit

  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing